|Rapid Review complete
|Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full pharmacoeconomic evaluation recommended at the submitted price.
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.